Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

432 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment.
Issa GC, Kantarjian HM, Gonzalez GN, Borthakur G, Tang G, Wierda W, Sasaki K, Short NJ, Ravandi F, Kadia T, Patel K, Luthra R, Ferrajoli A, Garcia-Manero G, Rios MB, Dellasala S, Jabbour E, Cortes JE. Issa GC, et al. Among authors: luthra r. Blood. 2017 Nov 9;130(19):2084-2091. doi: 10.1182/blood-2017-07-792143. Epub 2017 Aug 23. Blood. 2017. PMID: 28835440 Free PMC article. Clinical Trial.
Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia.
Verstovsek S, Tefferi A, Kantarjian H, Manshouri T, Luthra R, Pardanani A, Quintás-Cardama A, Ravandi F, Ault P, Bueso-Ramos C, Cortes JE. Verstovsek S, et al. Among authors: luthra r. Clin Cancer Res. 2009 Jan 1;15(1):368-73. doi: 10.1158/1078-0432.CCR-08-1302. Clin Cancer Res. 2009. PMID: 19118067 Free PMC article.
Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia.
Nazha A, Cortes J, Faderl S, Pierce S, Daver N, Kadia T, Borthakur G, Luthra R, Kantarjian H, Ravandi F. Nazha A, et al. Among authors: luthra r. Haematologica. 2012 Aug;97(8):1242-5. doi: 10.3324/haematol.2012.062638. Epub 2012 Apr 24. Haematologica. 2012. PMID: 22532519 Free PMC article.
Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS.
Kadia TM, Kantarjian H, Kornblau S, Borthakur G, Faderl S, Freireich EJ, Luthra R, Garcia-Manero G, Pierce S, Cortes J, Ravandi F. Kadia TM, et al. Among authors: luthra r. Cancer. 2012 Nov 15;118(22):5550-9. doi: 10.1002/cncr.27596. Epub 2012 May 8. Cancer. 2012. PMID: 22569880 Free PMC article.
FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Daver N, Strati P, Jabbour E, Kadia T, Luthra R, Wang S, Patel K, Ravandi F, Cortes J, Qin Dong X, Kantarjian H, Garcia-Manero G. Daver N, et al. Among authors: luthra r. Am J Hematol. 2013 Jan;88(1):56-9. doi: 10.1002/ajh.23345. Epub 2012 Oct 31. Am J Hematol. 2013. PMID: 23115106 Free PMC article.
Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.
Al-Kali A, Quintás-Cardama A, Luthra R, Bueso-Ramos C, Pierce S, Kadia T, Borthakur G, Estrov Z, Jabbour E, Faderl S, Ravandi F, Cortes J, Tefferi A, Kantarjian H, Garcia-Manero G. Al-Kali A, et al. Among authors: luthra r. Am J Hematol. 2013 May;88(5):365-9. doi: 10.1002/ajh.23410. Epub 2013 Mar 20. Am J Hematol. 2013. PMID: 23512829 Free PMC article.
Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months.
Nazha A, Kantarjian H, Jain P, Romo C, Jabbour E, Quintas-Cardama A, Luthra R, Abruzzo L, Borthakur G, Ravandi F, Pierce S, O'Brien S, Cortes J. Nazha A, et al. Among authors: luthra r. Haematologica. 2013 Nov;98(11):1686-8. doi: 10.3324/haematol.2013.090282. Epub 2013 Jun 28. Haematologica. 2013. PMID: 23812943 Free PMC article.
432 results